Orthex Q2 2026 slides: Nordic sales surge, but margins face pressure

Orthex’s Q2 net sales rose 5.2% to EUR 21.6m, but adjusted EBITA fell 17.6% to EUR 1.4m as gross margin compressed 3.2pp to 24.9% from surging polypropylene/propylene costs (driven by Middle East tensions). Rest of Europe sales dropped 10.5% to EUR 4.6m while the Nordics grew 12.0% to EUR 17.8m on execution of price increases, and management expects margin recovery later in 2026 once retailer pricing negotiations flow through. Despite the profitability squeeze, operating cash flow turned positive at EUR 1.8m and net debt fell EUR 4.3m to EUR 15.8m, with leverage improving to 1.1x.

Analysis

The market is likely over-focusing on headline growth and underpricing the lag between input-cost peaks and shelf-price realization. For SCPAF, the core issue is not demand collapse but margin timing: if polypropylene/propylene has already peaked, the P&L should inflect faster than the stock currently implies, but the next print can still look messy because retailer negotiations clear slowly. That makes this a 1-3 month catalyst story, not an immediate earnings beat story.

Competitive dynamics favor the brands and channels with the strongest pricing control. Orthex’s Nordic franchise looks resilient, but the weaker rest-of-Europe mix shows that distributors can temporarily switch to cheaper imports when the category is commoditized; that is a warning for other small-cap housewares and plastic-goods makers with less brand equity. The balance sheet is not the risk; the risk is that a prolonged resin spike or weak consumer traffic turns a transitory margin gap into a share-loss narrative.

The contrarian view is that the stock may already discount peak pain. If raw materials stabilize into late Q3 and management can show even modest gross-margin recovery, the equity can rerate sharply because the market is currently paying almost no value for the 2026 launch cycle and pricing reset. Falsifiers are clear: if gross margin stays sub-25% into the next report, or if pricing resets fail to offset inputs, the recovery thesis should be abandoned and the stock likely stays range-bound rather than recovering.

Key Decisions for Investors

• No fresh long in SCPAF into the next print; wait for evidence of gross-margin recovery and price realization. Reassess after the November update, when the first clean read on the pricing reset should be visible.
• If expressing the inflation view, use a 1-3 month pair: long upstream petrochemical/feedstock exposure such as LYB or WLK versus short SCPAF. The trade works if resin stays tight and margin lag keeps pressure on Orthex; cover if the input index rolls over quickly.
• Use a hard stop on any SCPAF long if the next reported gross margin fails to recover above the mid-20s or if management signals pricing negotiations are still unresolved. That would indicate the pass-through cycle is not working.
• For holders, sell strength rather than averaging down until the market proves that rest-of-Europe volumes can reaccelerate without sacrificing margin. The rerating only works once both volume and margin move together.
• Watch the polypropylene/proplylene spot and contract benchmarks as the primary catalyst indicator; if they remain elevated into September, expect another quarter of earnings revisions lower, not higher.